President Trump is promising lower drugs prices, but last month’s “deal” between the government and Pfizer is more about ...

The deals set a framework the White House will use to try to reach its goal of lowering U.S. prescription medicine prices.

AstraZeneca on Friday became the second big drugmaker after Pfizer to cut a pricing deal with the White House, announcing an ...

US President Donald Trump was due to make an announcement that a source said would confirm AstraZeneca as the second of 17 major pharmaceutical companies, after Pfizer, to agree to most-favored-nation ...

Wall Street investors bailed out of U.S. stocks on Friday after President Donald Trump threatened a "massive" tariff increase ...

Unlike peers, GSK plc faces limited Loss of Exclusivity risk, supporting steady revenue projections and justifying higher ...

Pfizer Inc "didn't conspire with anyone" to delay release of efficacy results for the COVID-19 vaccine it developed with German partner BioNTech SE until after the U.S. presidential election, Chief ...

Pfizer Inc Chief Executive Officer Albert Bourla sold $5.56 million worth of company shares on Monday, the day the drugmaker said its COVID-19 vaccine was 90% effective based on interim trial results, ...

As President Donald Trump's escalating tariff policies threaten to raise costs across global supply chains, one pharmaceutical giant is taking steps to protect its bottom line. On Sept. 30, ...

Shares of GoodRx ($GDRX), which provides drug coupons for discounts on medications, jumped over 5% on Thursday afternoon.

GoodRx (GDRX) stock jumps as its talks with White House on joining TrumpRx direct-to-consumer drug platform progress. Read ...

Trump and Pfizer said they reached a landmark deal to cut drug prices. Most Americans won't see a benefit, but Pfizer will.